ReviewCurrent diabetes reviews2026
An Insight on Flavonoids and Flavonoidsincorporated Nano-formulations in the Management of Diabetes Mellitus.
Review in Current diabetes reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Three-dimensional bioprinted hydrogels for the management of diabetic wounds: A review.BioImpacts : BI · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a worldwide health challenge and imposes a considerable strain on healthcare systems. By 2035, it is anticipated that around 592 million adults will be impacted by diabetes as a result of causes like aging, rapid population expansion, urbanization, obesity, lifestyle modifications, and heightened intake of calorie-dense, fatty, and fast meals. Despite the availability of several pharmaceutical therapies, they often come with higher expenses and adverse side effects, making them inaccessible to a large portion of the population. Bioactive compounds, especially flavonoids, are emerging as potential alternatives for diabetes management. Flavonoids, a category of polyphenolic chemicals included in fruits, vegetables, and various plant- derived foods, provide numerous therapeutic advantages. In addition to their glucose-lowering benefits, they increase antioxidant defence, improve insulin efficacy, and diminish the risk of cardiovascular problems. The clinical application of flavonoids is hindered by issues like poor solubility, low bioavailability, and complicated metabolism. This review explores the integration of nanotechnology- based delivery technologies to address these limitations. Advanced nano-formulations, such as polymeric nanoparticles, liposomes, micelles, and solid lipid nanoparticles, improve the solubility, stability, and absorption of flavonoids while facilitating targeted delivery and prolonged therapeutic benefits. The review highlights the efficacy of flavonoid-based nano-formulations in efficiently managing diabetes mellitus and its related problems. Moreover, it highlights the need for ongoing research to enhance these formulations and explore the molecular pathways that underlie their antidiabetic efficacy. This approach demonstrates the significance of nanotechnology in transforming diabetes care and enhancing patient outcomes.
Indexed as
Identifiers
40247806What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.